Skip to main content
. Author manuscript; available in PMC: 2016 Jul 25.
Published in final edited form as: Nephron Clin Pract. 2013 Jun 21;123(1-2):67–73. doi: 10.1159/000351684

Table 1.

Characteristics of the cohort according to the TNFA rs1800629 genotypes

Variable GG (n = 182) GA (n = 66) AA (n = 14) p
Age, years 65±16 66±15 70±12 0.485
Men 92 (50.6) 38 (57.6) 8 (57.1) 0.583
White ethnicity 161 (88.5) 62 (93.9) 14 (100) 0.198
BMI, kg/m2 30±9 30±7 33±7 0.432
Coexisting conditions
  Diabetes mellitus 79 (43.4) 30 (45.5) 7 (50.0) 0.870
  Heart failure 30 (16.5) 9 (13.6) 3 (21.4) 0.736
  Sepsis 76 (41.8) 30 (45.5) 6 (42.9) 0.874
Baseline eGFR <60 ml/min/1.73 m2 118 (65.9) 44 (69.8) 12 (85.7) 0.291
AKI stage
  Stage 1 85 (46.7) 23 (35.4) 4 (28.6) 0.268
  Stage 2 6 (3.3) 5 (7.7) 1 (7.1)
  Stage 3 91 (50.0) 37 (56.9) 9 (64.3)
Cause of AKI
  Ischemic 64 (35.4) 23 (34.9) 7 (50.0) 0.794
  Nephrotoxic 30 (16.6) 11 (16.7) 0 (0.0)
  Sepsis 19 (10.5) 4 (6.1) 1 (7.1)
  Atheroembolic 9 (5.0) 4 (6.1) 1 (7.1)
  Other/unknown/multifactorial 59 (32.6) 24 (36.4) 5 (35.7)
ICU admission 133 (73.1) 48 (72.7) 11 (78.6) 0.898
Assisted mechanical ventilation 46 (25.3) 13 (19.7) 3 (21.4) 0.646
APACHE II score 20±7 19±5 21±8 0.428
Enrollment serum cystatin C, mg/l 3.0±1.2 3.1±1.1 4.0±1.7 0.039
Serum creatinine, mg/dl
  Enrollment 3.4±1.6 3.9±2.0 4.0±1.6 0.084
  Peak 4.0±1.9 5.2±3.9 4.8±1.9 0.004
  Discharge 2.3±1.4 3.1±2.3 2.0±0.9 0.004
Urinary tubular injury marker
  KIM-1, ng/mg 2.9 (1.2, 7.4) 4.9 (2.4, 9.3) 6.7 (3.3, 9.3) 0.034
  NAG, mU/mg 39.9 (17.0, 87.6) 29.6 (12.1, 76.3) 32.7 (15.7, 114.9) 0.333
  α-GST, ng/mg 15.6 (6.0, 35.7) 10.7 (3.7, 29.8) 19.3 (7.9, 50.1) 0.458
  π-GST, ng/mg 274.0 (97.0, 826.9) 274.5 (61.8, 1,062.5) 1,397.3 (1,164.7, 2,440.9) 0.031
Oliguria, % 33 (18.4) 14 (21.9) 4 (28.6) 0.589
Dialysis requirement 68 (37.4) 27 (40.9) 8 (57.1) 0.329
In-hospital death 39 (21.4) 13 (19.7) 5 (35.7) 0.411

Continuous variables are presented as means (SD) or medians (25th and 75th percentile), and categorical variables as n (%).